Neochem Bio Solutions Limited is set to launch its SME Initial Public Offering (IPO) from 2nd December 2025 to 4th December 2025. This SME IPO will follow a 100% book building process and is attracting significant attention from investors. Neochem Bio Solutions Limited is a leading biotech and healthcare company focused on developing innovative solutions for the life sciences sector. The company specializes in high-quality bio-products and research-driven solutions catering to both domestic and international markets.
Neochem Bio Solutions IPO Key Details
| Parameter | Details |
|---|---|
| Company Name | Neochem Bio Solutions Limited |
| Symbol | NEOCHEM |
| Issue Period | 02-Dec-2025 to 04-Dec-2025 |
| Cut-off Time for UPI Mandate Confirmation | 04-Dec-2025 (up to 5:00 PM) |
| Issue Size | Up to 45,88,800 Equity Shares (including 2,32,800 shares for Market Maker) |
| Issue Type | 100% Book Building |
| Price Range | Rs. 93 to Rs. 98 per share |
| Lot Size | 1,200 Equity Shares |
| Face Value | Rs. 10 per share |
UPI Mandate Instructions
- The cut-off time for UPI mandate confirmation is 5:00 PM on the last day of the IPO.
- Only bids with confirmed UPI mandate (RC100) will be considered valid.
- Investors are advised to submit UPI applications well in advance to avoid last-minute technical or systemic issues.
Lot Size & Investment Example
- Minimum Lot Size: 1,200 shares
- Price Band: Rs. 93 – Rs. 98
- Investment for 1 Lot:
- Minimum: 1,200 × 93 = Rs. 1,11,600
- Maximum: 1,200 × 98 = Rs. 1,17,600
Investors can apply in multiples of 1,200 shares if they wish to invest in more than one lot.
Why Investors Are Watching Neochem Bio Solutions IPO
Neochem Bio Solutions operates in the biotech/healthcare sector, a high-growth industry.
- The fresh issue portion of the IPO will be used for business expansion and growth.
- With a price band of Rs. 93–98, the IPO is considered moderately priced, making it attractive for retail investors.
Disclaimer: This article is for informational purposes only. Investors should consult their financial advisor before making any investment decisions.
Source- NSE
I am a finance writer focused on IPO updates, market trends and equity research. I simplify complex IPO data into clear, accurate and reliable insights to help readers stay informed.